SPRB

Spruce Biosciences, Inc.

SPRB | News | $0.705 0.54% 0.54% 420K

(0.0% 1d) (0.0% 1m) (-66.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-56.25% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 29,012,594
http://www.sprucebiosciences.com
Sec Filling | Patents | 17 employees

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

endocrine msa

add to watch list Paper trade email alert is off

Press-releases

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Published: 2024-04-22 (Crawled : 23:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| 0.0% | O: -2.86% H: 2.94% C: 1.47%
presentation endocrine meeting

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -85.89% | O: 0.0% H: 5.85% C: 4.64%
year financial results

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
Published: 2024-01-22 (Crawled : 14:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -70.71% | O: -1.26% H: 5.08% C: 3.39%
study

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
Published: 2024-01-05 (Crawled : 14:30) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -75.69% | O: 2.08% H: 1.36% C: 0.0%

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -74.36% | O: -1.1% H: 10.37% C: 6.67%
program

Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -55.7% | O: -0.95% H: 0.32% C: -12.14%
study

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-08-28 (Crawled : 22:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -67.89% | O: 1.83% H: 1.97% C: 1.35%
conference global

Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Published: 2023-05-15 (Crawled : 13:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M

Health Technology

| -3.26% | O: 0.14% H: 0.31% C: -0.72%
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -68.61% | O: -5.04% H: 4.84% C: 2.95%
financial results

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
Published: 2023-03-16 (Crawled : 23:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -69.03% | O: -0.88% H: 4.91% C: 2.23%
year financial results

Spruce Biosciences Announces $53.6 Million Private Placement Financing
Published: 2023-02-09 (Crawled : 19:00) - biospace.com/
SPRB | News | $0.705 0.54% 0.54% 420K

Health Technology

| -77.92% | O: 7.57% H: 4.69% C: -12.02%

See all